PTC/SB/08a (08-03)
Approved for use through 97/31/2006, ONE 0651-0231
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number.

	Application Number				
	Filing Date				
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Liewr	n Zhang		
Not for submission under 37 CFR 1.99)	Art Unit				
not for submission and or or it is of	Examiner Name				
	Attorney Docket Number	r	LIP-104US		

					U.S.	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue E	Issue Date Name of Patentee or Applica of cited Document			Pages,Columns,Lines where Relevant Passages or Releva Figures Appear		
	1	5851290A		1998-1	2-22	Tissue Engine	sering INC			
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	lease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Patentee or Applicant of cited Document		Relev	s,Columns,Lines whe ant Passages or Rele es Appear	
	1									
If you wis	h to a	dd additional U.S. Publ	ished Ap	,		n information p		d butto	n. Add	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Countr Code <sup>2</sup>	y	Kind Code4	Publication	Name of Patente Applicant of cited Document	ant of cited where Rele		74
	1	CN1446961A	CN			2003-10-08	Shousong Cheng			
	2	JP7-97714A	JP			1995-04-11	Mitsubishi Rayon (	Co Ltd		
	3	EP1229156A	EP			2002-08-07	Kaneka Corp			Ī

# Application Number | Filing Date | First Named Inventor | Leven Zhang | Art Unit | Leven Zhang | Application Number | Leven Zhang | Application Number | Filing Date | Fine Number | Leven Zhang | Application Number | Filing Date | Fine Number | Leven Zhang | Application Number | Fine Number | Leven Zhang | Application Number | Fine Number | Leven Zhang | Application Number | Fine Number | Leven Zhang | Application Number | Fine Number | Leven Zhang | Application Number | Fine Number | Leven Zhang | Application Number | Fine Number | Leven Zhang | Application Number | Fine Number | Leven Zhang | Application Number | Fine Number | Leven Zhang | Application Number | Fine Number | Leven Zhang | Application Number | Fine Number | Leven Zhang | Application Number | Fine Number | Leven Zhang | Application Number | Fine Number | Leven Zhang | Application Number | Fine Number |

If you wish	h to a	additional Foreign Patent Document citation information please click the Add button Add	_
		NON-PATENT LITERATURE DOCUMENTS Remove	_
Examiner Initials*	Cite No	clude name of the author (in CAPITAL LETTERS), itile of the article (when appropriate), tile of the item ook, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), tillsher, city and/or country where published.	Γs
	1		
If you wis	h to a	additional non-patent literature document citation information please click the Add button Add	Т
		EXAMINER SIGNATURE	_
Examiner	Signa	Date Considered	Τ
		1 Variation of the state of the	_

1 See Kin Codes of USPTO Patent Documents at work ISETO.GGU/or MPEP 901.04. 2 Enter office that issued the document, by the hor-letter code (WIPO Standard ST3.) 2 for Just purspece patent out contents, the included not the year of the register own precedule the single interpretation of the petent of the peten

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## Application Number Fling Date Fling Managed Inventor | Liewn Zhang Art Unit Examiner Name | L

### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s);

That each item of information contained in the information disclosure statement was first cited in any communication if from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eVI).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, not not information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/9/(c).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

□ None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Tianhua Gu/	Date (YYYY-MM-DD)	2006-09-17
Name/Print	Tianhua Gu	Registration Number	52480

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, V.S. Organization (1 Patent and Tradenar's Office, V.S. Organization (2 Patent and Tradenar's Office, V.S. Organiz

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.